Solutions

NEW YORK TIMES  by Rick Gladstone                                                                   March 12, 2015 

The president of Liberia acknowledged on Wednesday that she had erred in ordering a tough security crackdown at the height of the Ebola crisis last year, describing the deadly virus as an “unknown enemy” that had frightened her.

Liberian President Ellen Johnson Sirleaf during a video address last Deceber to the Senate Foreign Relations Committee

PALO ALTO WEEKLY by My Nguyen                      March 6, 2015
PALO ALTO, California -- 

...Malan and Philip Joubert, brothers from South Africa who recently moved to Palo Alto to expand their app-development company, Journey, saw the demand for mobile solutions, so they created the Ebola Care app to help aid organizations in Liberia, Sierra Leone and Guinea. 

 The app has several core functions, including contact tracing, which identifies and diagnoses people who may have come into contact with an infected person; quarantine management, which tracks and manages the 21-day quarantine period of a patient; psychological assessments to determine the well-being of health workers; social work to build case files for orphaned children; survivor surveys, which are assessments of Ebola survivors upon leaving treatment centers; verification that supplies have been distributed; and event feedback, which captures thoughts from the community after educational events.

COMMENTARY: Foreign leaders discussing solutions to the Ebola epidemic must acknowledge the contribution made by local workers to reduce infection rates

     International response … leaders of Ebola-hit countries in west Africa and EU commissioners attend a conference in    Brussels on Ebola on Tuesday 3 March. Photograph: Thierry Charlier/AFP/Getty Images

THE GUARDIAN by James Fofanah                                                                    March 3, 2015

...The international community’s initial focus on a purely medical response – and a megaphone broadcast of the over-simplistic message that “Ebola is real” – was a failure, and a major reason for the rapid spread of the disease at the early-to-middle stages of the epidemic.

FORBES   by   David Kroll                                                                                          March 1, 2015

The widely-discussed antibody cocktail, ZMapp, is finally going to be tested under standardized, controlled conditions for its safety and efficacy in Ebola virus disease-infected patients in Liberia and, potentially, the United States.

Late Friday, the NIH National Institute of Allergy and Infectious Disease (NIAID) announced the launch of a randomized trial in up to 200 patient volunteers with confirmed Ebola virus infections.

The two-arm study will compare supportive standard of care with or without three intravenous infusions of ZMapp spaced three days apart. This is the same dosing regimen published in Nature that protected 18 of 18 monkeys when given up to five days after experimental infection.

LeafBio, the commercial arm of San Diego-based Mapp Biopharmaceutical, announced concomitantly that the FDA had approved their IND for this trial. The three antibodies that comprise ZMapp target both distinct and overlapping parts of the Ebola virus glycoprotein (GP) that it uses to infect humans.